Guardion Health Sciences — Investor Presentation (June 2021)
25 slides from Guardion Health Sciences's investor presentation, Jun 9, 2021
Slide 1: Corporate Presentation
HEALTH SCIENCES Corporate Presentation Nasdaq: GHSI June 2021
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT This presentation of Guardion Health Sciences, Inc. (the “company,” “Guardion,” “we,” “us,” or “our”) includes "forward-looking statements" intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These stat
Slide 3: About Guardion Health Sciences
About Guardion Health Sciences Guardion Health Sciences (Nasdaq: GHSI), is a clinical nutrition and diagnostics company. GHSI offers a portfolio of science-based, clinically supported nutritional supplements, medical foods, and diagnostic products that support healthcare professionals, their patient
Slide 4: Corporate Statistics
Corporate Statistics Market Stats FY2020 Revenue by Segment Trading Symbol Nasdaq: GHSI ™ Medical Foods and Nutraceuticals = ™ Medical Devices (Ee Q S&S & ss Nasdaq: GHSI
Slide 5: Investment Highlights
Investment Highlights * Well-positioned to compete in ~$150B nutrition market with differentiated and established product portfolio of proven nutrition, and medical foods with a focus on bone, ocular, and immune health “ Recent $26M acquisition of Activ Nutritional, LLC and its well-known Viactiv® l
Slide 6: Nutrition — Large, Growing, Global Market
Nutrition — Large, Growing, Global Market All segments - supplements, clinical nutrition & medical foods - showing strong growth Global Supplement and Medical Food Global Players fesk [Phizer) 400 Market Size and Growth (2020-2030) B => 300 [= 2 Anticipated Industry Growth Rates? eS) =} g Immune Sup
Slide 7: U.S. Dietary Supplement Industry - $50B+ market
U.S. Dietary Supplement Industry - $50B+ market U.S. Supplement Industry Sales & Growth, 2015-2023e Delivery forms with at or above industry growth $70 14% reflect significant consumer attention that could outlast the pandemic. $60 12% 380 40% Delivery Form 2020-2023 CAGR Pill Pack 83% BD sa0 em Sho
Slide 8: Clinical Nutrition Industry
Clinical Nutrition Industry FOOD VITAMINS, SUPPLEMENTS, MEDICAL FOODS _—— iC» PHARMACEUTICALS —ey = CLINICAL NUTRITION Abbott Nurton eee N le Meadjoj > Clinical nutrition - The use of diet and nutritional supplements as a way to enhance health (and) prevent disease. Clinical nutrition is a disciplin
Slide 9: Growth Drivers of Clinically Supported Nutrition
Growth Drivers of Clinically Supported Nutrition a Increasing awareness of the importance of nutrition ** Growing body of research demonstrating benefits of nutrition “* Increasing geriatric population with unique nutritional needs * Specific to eye care, publication of highly prominent AREDS study
Slide 10: Viactiv®/Bone Health
Viactiv®/Bone Health GUARDION
Slide 11: Viactiv® Product Line
Viactiv® Product Line HEALTH SCIENCES \ Viactiv. Viactiv. Calcium sae Calcium aap 3 Be Viactiv Calcium #1 Calcium chew with 650mg per chew (2 chews = 100% DV); most calcium vs. gummies and chews & 2/3 less sugar vs. calcium gummies; only one with Vitamins D & K Viactiv Calcium + Immune Orange cream-
Slide 12: U.S. Mineral Supplement Industry
U.S. Mineral Supplement Industry Revenue ($B) U.S. Mineral Sales Growth, 2006-2021e' 2005 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017e 2018e 2019e 2020e 2021e Mineral consumer retail sales are growing and projected to reach $3.5B in sales in 2021 {2007 Nutrition Business Journal ($Mil, co
Slide 13: Recently Announced Acquisition of Viactiv® Product Line
Recently Announced Acquisition of Viactiv® Product Line “» June 2021 — Closed $26M acquisition of Viactiv® line of supplement chews for bone and immune health > immediately becomes our flagship consumer brand “* Strong brand within the Calcium dietary BOUTOFIO ‘OB/GYNS supplement category with stron
Slide 14: Recently Announced Acquisition of Viactiv® Product Line (cont.)
Recently Announced Acquisition of Viactiv® Product Line (cont.) “* Viactiv is currently marketed through large retailers, including ‘ Why Viacti ther brands? Walmart, Target, CVS, and Amazon and is the #1 chew and the #2 A perfect balance of TASTE & EFFICACY combined chew/gummy brand Itis the best t
Slide 15: Ocular Health
Ocular Health GUARDION
Slide 16: Opportunity in the Large Ocular Health Sector
Opportunity in the Large Ocular Health Sector The ocular nutrition market is expected to grow at a 6% CAGR, driven by Age-related Macular Degeneration (“AMD”) and glaucoma, which are primary treatment focus areas of Guardion Market Value (US $ Bn) Re oO RB a oN 4.0 0.8 02 i q2 14 2020 = AMD = Dry Ey
Slide 17: Company's Ocular Health Products
Company's Ocular Health Products HEALTH SCIENCES Lumega-Z (“LMZ”): GlaucoCetin MapcatSF CSV-2000 Designed to replenish Designed to support The Company licensed a Standardized contrast and restore the and protect the proprietary technology, sensitivity testing macular protective mitochondrial functio
Slide 18: Immune Health
Immune Health GUARDION
Slide 19: Opportunity in A Growing Sector
Opportunity in A Growing Sector Immune Health $37.7 Billion Key Market Drivers Increasing health consciousness and awareness of nutrition among patients and providers wo w oa for) o 2 os cy + Growing at-risk geriatric population nN a + Rising rate of chronic immune illnesses Market Value (US $ Bn) N
Slide 20: Company's Immune Health Products
Company's Immune Health Products NutriGuard ImmuneSF Nutritional supplement product developed under the Nutriguard brand, designed to support effective immune function HEALTH SCIENCES } —, — rot It is) — Astramern Astra H Malaysia Customized, “private label” product that contains specifically formul
Slide 21: Growth Strategy
Growth Strategy
Slide 22: Current Growth Initiatives
Current Growth Initiatives ti Integrate Viactiv® acquisition successfully * Continued retail and online channel growth of Viactiv product line “+ Leverage Viactiv’s distribution and marketing capabilities to expand sales of all products 2; Evaluate brand strategy, product portfolio and M&A opportuni
Slide 23: Current Growth Initiatives (continued)
Current Growth Initiatives (continued) 4. Strengthen the relationship with the health care providers *» Developing highly-targeted virtual education programs *» Developing professional education for eye care professionals 5. Strengthen clinical evidence to create differentiation *» Identify opportun
Slide 24: Leadership Team
Leadership Team VA Bret Scholtes David W. Evans, PhD Andrew Schmidt Susan Klein, ND Craig J. Sheehan Director Director Vice President and Chief Director of Chief Commercial Officer Chief Executive Officer Chief Science Officer Financial Officer Medical Education President Robert N. Weingarten Mark G
Slide 25: For More Information
HEALTH SCIENCES FOR MORE INFORMATION: Investor Relations CORE IR Scott Arnold (516) 222-2560 [email protected] guardionhealth.com Nasdaq: GHSI GUARDION
Guardion Health Sciences — Investor Presentation (June 2021) on 6ix